Fierce Biotech June 24, 2024
Novo Nordisk has shared a closer look at phase 3 results on its hemophilia A candidate Mim8, revealing new data that show how it squares up against Roche’s blockbuster Hemlibra on key measures of efficacy and tolerability.
In May, Novo reported topline results from the study, which Jefferies analysts said “may near our ‘best’ case scenario, with convenient once-monthly dosing seeming similarly effective to once-weekly, and efficacy data that may challenge Roche’s incumbent Hemlibra.” However, the initial readout lacked a look at annualized bleed rates (ABR), focusing instead on percentage changes, or injection site reactions.
Novo filled in the gaps in the dataset in a presentation at the International Society of Thrombosis and Haemostasis Annual Congress over the weekend....
Today's Sponsors
Today's Sponsor